Medera’s SPAC Merger Marks Rare Biotech Move
Medera aims for Nasdaq listing via SPAC to boost gene therapies, spotlighting rare biotech SPACs in 2024.
- Latest
- Trending
Medera aims for Nasdaq listing via SPAC to boost gene therapies, spotlighting rare biotech SPACs in 2024.
Interlynk to provide SBOM generation, vulnerability reporting, and risk assessment for BIOTRONIK's life-saving products.
"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.